Ruan, Hang
Xiang, Yu
Ko, Junsuk
Li, Shengli
Jing, Ying
Zhu, Xiaoyu
Ye, Youqiong
Zhang, Zhao
Mills, Tingting
Feng, Jing
Liu, Chun-Jie
Jing, Ji
Cao, Jin
Zhou, Bingying
Wang, Li
Zhou, Yubin
Lin, Chunru
Guo, An-Yuan
Chen, Xi
Diao, Lixia
Li, Wenbo
Chen, Zhiao
He, Xianghuo
Mills, Gordon B.
Blackburn, Michael R.
Han, Leng http://orcid.org/0000-0002-7380-2640
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RR150085)
Article History
Received: 9 February 2019
Accepted: 9 August 2019
First Online: 26 August 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: G.B.M. has sponsored research support from AstraZeneca, Critical Outcomes Technology, Karus, Illumina, Immunomet, Nanostring, Tarveda, and Immunomet and is on the Scientific Advisory Board for AstraZeneca, Critical Outcomes Technology, ImmunoMet, Ionis, Nuevolution, Symphogen, and Tarveda. The remaining authors declare that they have no competing interests.